The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. 
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The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies.
With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S]ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous (i.v.) injection of AS [S]ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS [S] ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs (S[S]ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS [S] ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[S]ODNs treatment. Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases (MAPK) was abolished in tumors growing in AS[S]ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS [S] ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by Introduction Type I insulin-like growth factor receptor (IGF-IR) plays a pivotal role in the regulation of cell growth in different ways. It is not only mitogenic for several cell types but also plays a crucial role in the establishment and maintenance of the transformed phenotype, protects cells from a variety of apoptotic signals and finally also induces differentiation of certain cell types (for review see Werner and Le Roith, 2000) . Evidence of a crucial role of IGF-IR in malignant transformation was first provided by the findings of Sell et al. (1994) , showing that mouse embryo cells with a targeted disruption of IGF-IR (R-cells) cannot be transformed by SV40T antigen and/or activated Ha-ras oncogene both of which easily transform embryo cells obtained from wild-type littermates. This finding has since then been confirmed with several viral and cellular oncogenes that also fail to transform R-cells (reviewed in Baserga, 1999) .
A growing body of evidence indicates that IGF-IR plays a key role in breast cancer development and that it is involved in a complex cross-talk with steroid hormones that regulates breast tumor growth (reviewed in Surmacz et al., 1998) . High levels of IGF-IR expression have been found in breast tumors and breast cancer cell lines (reviewed in Surmacz et al., 1998) . However, accumulating evidence supports the hypothesis that an obligatory requirement to establish and maintain the transformed phenotype is the presence of physiological levels of IGF-IR instead of overexpression of this receptor (reviewed in Yu and Rohan, 2000) .
We have already demonstrated that IGF-IR plays a key role in the proliferation of C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in female Balb/c mice. As we have previously described in detail (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 , C4HD tumors are of ductal origin, require MPA administration to proliferate both in vivo and in in vitro, and express high levels of estrogen (ER) and progesterone receptors (PR) (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 ). C4HD tumors also express IGF-IR and synthesize IGF-I (Elizalde et al., 1998) . In previous works, we found that blockage of IGF-IR expression by using antisense oligodeoxynucleotides (ASODNs) to IGF-IR mRNA, inhibited MPA-stimulated growth of primary cultures of epithelial cells from C4HD tumor (Elizalde et al., 1998) , indicating that a functional autocrine loop involving IGF-I and IGF-IR participates in MPA-induced proliferation of C4HD cells. On the other hand, our studies of the expression and function of type I receptor tyrosine kinases (RTKs: EGF-R/ErbB-1, ErbB-2, ErbB-3 and ErbB-4), and their ligand, heregulin (HRG), revealed the existence of bi-directional crosstalks between progestins and HRG/Erbs signaling pathways that control C4HD cell growth (Balana et al., 1999 (Balana et al., , 2001 . Finally, we found interaction between IGF-IR and HRG/ErbBs signaling, evidenced first by the fact that HRG induced a potent proliferative response in C4HD cells, which was completely abolished by the blockage of IGF-IR expression using ASODNs (Balana et al., 1999) ; second, by the presence of a hierarchical interaction between IGF-IR and ErbB-2, by which IGF-IR directs ErbB-2 phosphorylation (Balana et al., 2001) . As a whole, our findings consistently identify IGF-IR as playing a key role in C4HD cell proliferation driven by three different but related pathways, that is, by the PR, by HRG/ErbBs and lastly by its own IGF-I/IGF-IR autocrine loop.
In the present study, we have assessed the effect of targeting IGF-IR with antisense strategies in in vivo growth of C4HD tumors. Our findings for the first time demonstrated that either direct intratumor injection or systemic administration of phosphorothioate antisense ODNs (AS[S]ODNs) to IGF-IR mRNA resulted in a significant growth inhibition of C4HD tumors. In addition, we dissected a network of interactions among IGF-IR, type I RTKs, and PR signaling pathways that were differentially affected by blockage of IGF-IR function.
Results

Effects of IGF-IR AS[S]ODNs on C4HD cell in vitro proliferation
The aim of the present study was to explore the effect of the abolishment of IGF-IR expression, by using ASODNs, in in vivo growth of C4HD tumors. To overcome the rapid degradation of the phosphodiester ODNs by nucleases, we used phosphorothioate ODNs ([S]ODNs) in the experiments carried out in vivo. Here, we first compared the ability of the AS[S]ODNs to IGF-IR to inhibit in vitro proliferation of C4HD cells with the effect of their unmodified counterparts, the phosphodiester ASODNs, which we had already used in our previous studies (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 . As shown in Figure 1a , phosphorothioate AS[S]ODNs are able to exert a dose-dependent inhibition of MPA-induced C4HD cell growth, comparable to the one exerted by the phosphodiester ASODNs. Sense [S]ODNs had no effect on proliferation at any of the tested doses. The effect of IGF-IR AS[S]ODNs on protein expression was assessed by immunoblotting Mice were injected directly into the tumor with 100 mg/day/mice AS[S]ODN (.) (n ¼ 10), S[S]ODN (m) (n ¼ 10), or 100 ml of PBS (') (n ¼ 10) for a total of 14 days. Tumor length and width were measured daily and tumor volume was calculated as described in Material and methods. At day 15 half the animals in each group were killed and tumors were excised. Each point represents the mean volume7s.e. of 10 independent tumors during the first 15 days and of five tumors during days 16-21 Systemic treatment of solid tumors with antisense oligonucleotides is currently under investigation in several trials (Tamm et al., 2001) . Therefore, positive results obtained in the intratumoral protocol encouraged us to assess the effect of intravenous (i.v.) injection of AS[S]ODNs on C4HD tumor growth. In the first series of experiments, mice were injected i.v. via the retroorbital venous sinus, with 0.25 mg/day/mouse AS[S]ODNs or S[S]ODNs for 7 days. A third group was inoculated with the vehicle (100 ml PBS). From now on, we will be referring to this experimental approach as low-dose protocol. As shown in Figure 3a In an effort to improve treatment with systemic AS[S]ODNs in the last experimental design, which we will be referring to as high-dose protocol, we rose [S]ODNs dose to 1 mg/day/ mouse from day 1 to day 14 of treatment. As seen in Figure 3b , the inhibitory effect of AS[S]ODNs was evident from the beginning of the treatment. This systemic treatment proved to be highly effective to inhibit tumor growth (Table 1) . A delay of 6 days in tumor growth with respect to S[S]ODN and PBS administration was observed at day 15 when, as described for the other two therapeutic schedules, tumors were excised from half the mice in each group. As already seen in the intratumoral protocol, in both intravenous protocols, differences observed in tumor growth and in growth rates were evident and significant 1 week after the end of the treatment on day 21 (Table 1) . No statistically significant differences either in tumor growth, in growth rates or in growth delay between S[S]ODN and PBS control groups were observed in any of the experimental schedules (Table 1) .
There were no signs of overt toxicity in mice treated with AS[S]ODNs either in intratumoral or in intravenous experiments and no significant changes in serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose and creatinin were found between AS[S]ODN-treated and control groups (data not shown). In addition, we did not observe weight loss in mice receiving AS [S] ODNs in any of the three experimental protocols which evidences good tolerance by animals of the three experimental regimens. ODN-or PBStreated animals, both of which showed over 10 mitoses per 10 HPF. Histopathological images of tumors from the intratumoral or low-dose intravenous protocols were similar to those observed in the high-dose treatment group (data not shown). In addition, histological examination of liver, lung, heart and pancreas did not reveal any pathological changes (data not shown).
Histhopathogical analysis
Morphology of tumors from AS[S]ODN-, S[S]ODN-or
Molecular mechanisms involved in the antitumoral effect of IGF-IR AS[S]ODNs
Since we achieved a significant though incomplete inhibition of C4HD tumor growth by IGF-IR AS[S]ODN administration, we had tumor samples available to explore signaling pathways disrupted in vivo by targeting IGF-IR.
To establish first whether the antitumor effect in vivo was due to a specific antisense effect, IGF-IR expression in tumors from AS[S]ODN-, S[S]ODN-and PBS-treated mice was evaluated in protein extracts from tumors excised at day 15. As control, we included C4HD tumors growing in MPA-untreated animals ( Figure 5a , MPA-U). As shown in Figure 5a An essential step in signal transduction from IGF-IR is the phosphorylation of insulin receptor substrate-1 (IRS-1). Of the downstream signals activated by IRS-1, the best characterized is the PI-3K/Akt pathway (Backer et al., 1993; Scrimgeour et al., 1997 and references within) . Here, we assessed IRS-1 phosphorylation state and PI-3K/Akt activation as a way to identify signaling pathways affected in vivo by the abolishment of IGF-IR We had already shown the existence of a hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 phosphorylation in breast cancer cells (Balana et al., 2001) , and had already reported that blockage of IGF-IR with ASODNs did not affect the levels of ErbB-2 protein expression in primary cultures of C4HD cells (Balana et al., 1999 ). In our current study, we found that AS[S]ODNs did not regulate ErbB-2 content in vivo in any of the protocols and also found that ErbB-3 levels remained unaffected by AS[S]ODN treatment (data not shown). We then assessed ErbB-2 and ErbB-3 phosphorylation state in tumors obtained from all three experimental regimens, as a marker of their activation. As we have already found in C4HD tumors growing in MPA-treated mice (Balana et al., 1999 (Balana et al., , 2001 ), we detected a strong degree of ErbB-2 and ErbB-3 tyrosine phosphorylation in both PBS and S[S]ODN control groups (Figure 7a , upper panels in each protocol, lanes 1, 2, 4 and 5). Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of both ErbB-2 and ErbB-3 tyrosine phosphorylation as compared to tumors growing in S[S]ODN-or in PBS-treated mice (Figure 7a , upper panels in each treatment, lanes 3 and 6). These findings provide the first demonstration that blockage of IGF-IR expression in vivo leads to inhibition of ErbB-2 and ErbB-3 tyrosine phosphorylation. The presence of heterodimers between ErbB-2 and ErbB-3 was investigated by immunoprecipitating tumor extracts with an anti-ErbB-2 antibody and by revealing Western blots with an anti-ErbB-3 antibody. Figure 7b shows that while heterodimers between ErbB-2 and ErbB-3 are readily detectable in PBS-and in S[S]ODN-treated mice (upper panels in each protocol, lanes 1 and 2), a . Similar results were found when tumor extracts were immunoprecipitated with an anti-ErbB-3 antibody, and Western blotting was performed with an anti-ErbB-2 antibody (data not shown). We were then for several reasons interested in assessing the effect of IGF-IR AS[S]ODNs on mitogen-activated protein kinases (MAPK) activity. First, it is well acknowledged that IGF-IR activates the MAPK/ Erk signaling pathway, mainly through Shc proteins, another IGF-IR major substrate (Scrimgeour et al., 1997 and references within, Sasaoka et al., 1994) . Second, the key proliferative stimulus in our tumor model is driven by MPA acting through the PR. Multiple lines of evidence, including our own work (Labriola et al., 2003) , suggest that MAPK-induced phosphorylation plays a role in PR function (Lange et al., 2000; Shen et al., 2001; Qiu et al., 2003) . Finally, breast cancer often shows elevated MAPK activity that has been associated to loss of estrogen response and development of metastasis (Adeyinka et al., 2002) . Figure 8 shows results of the intravenous high-dose protocol. All tumors expressed p42/p44 MAPK (lower panel). MAPKs activation was readily detectable in tumors from control groups by performing Western blot using an antibody specific for the dually phosphorylated, active form of this kinase (Figure 8 3 and 4) . This is in accordance with our previous results demonstrating that MPA induces MAPK activation in vitro (Labriola et al., 2003) .
Recent evidence has clearly shown the presence of bidirectional cross-talks between steroid hormones and growth factors (GFs) signaling pathways (Ignar-Trowbridge et al., 1992; Pietras et al., 1995; Lange et al., 1998; Migliaccio et al., 1998; Balana et al., 1999 Balana et al., , 2001 Boonyaratanakornkit et al., 2001; Shen et al., 2001; Labriola et al., 2003) . Accumulating evidence has demonstrated interactions between ER and IGF-I/ IGF-IR signaling pathways (Stewart et al., 1990; Lee et al., 1999; Oesterreich et al., 2001) . However, less information is available about cross-talks between IGF-IR and PR (Katzenellenbogen and Norman, 1990; Cho et al., 1994; Cui et al., 2003) . Therefore, we next investigated whether blockage of IGF-IR expression might affect PR expression and/or activity. First, we evaluated PR expression levels. The results obtained in the intravenous high-dose protocol are shown in Figure 9 . Similar PR protein levels were detected in tumors from mice treated with AS[S]ODNs (lower panel, lanes 5 and 6) as compared to those found in tumors from control groups (lower panel, lanes 1-4). Same results were found in the other therapeutic schedules (data not shown). Recent findings by Lange and co-workers (Lange et al., 2000; Shen et al., 2001) demonstrated that phosphorylation of PR on Ser294 directly correlates with PR transcriptional activity. Therefore, we herein assessed the state of PR Ser294 phosphorylation in an attempt to evaluate whether abrogation of IGF-I/IGF-IR signaling could interfere with the activation of PR. As shown in Figure 9 , PR phosphorylation on Ser294 was detected in PBS and S[S]ODN control groups (upper panel, lanes 1-4), in accordance with our previous in vitro findings, demonstrating that MPA was able to induce PR Ser294 phosphorylation (Labriola et al., 2003) . Tumors from AS[S]ODN-treated mice (upper panel, lanes 5 and 6), showed levels of Ser294 phosphorylation comparable to those found in control groups. We could not detect Ser294 phosphorylation of the PRA isoform in these in vivo tumor samples. This might be explained by the fact that, as previously reported (Clemm et al., 2000) , anti-Ser294 antibody exhibited strong preferential reactivity for PRB. Same results were found in the other experimental protocols (data not shown). We found our result with PR particularly remarkable for it indicates that C4HD tumor cells display high levels of PR Ser294 phosphorylation in spite of IGF-IR expression blockage, which leads to a significant decrease of MAPK activity (Figure 8 ). Since a key feature of our model system is that blockage of IGF-IR expression proceeds in the continuos presence of MPA, this finding suggests that ligand-induced PR Ser294 phosphorylation occurs via MAPK-independent pathways.
Discussion
In the present study we have demonstrated that either intratumor or systemic administration of phosphorothioate antisense ODNs to IGF-IR mRNA resulted in Tumor extracts (500 mg) were immunoprecipitated with an ErbB-2 antibody, and immunocomplexes were subjected to electrophoresis and analysed by Western blotting with an ErbB-3 antibody. Membranes shown in upper panels of each protocol were stripped and hybridized with an anti-ErbB-2 antibody (lower panels). In lane 4, as control, 500 mg of protein extracts from tumors growing in PBStreated mice were incubated with preimmune rabbit serum, and then Western blot was performed with anti-ErbB-2 and ErbB-3 antibodies. W: Western blot, IP: Immunoprecipitation Antisense IGF-IR therapy of breast cancer M Salatino et al a significant growth inhibition of the C4HD mouse mammary tumor line, our experimental model of mammary carcinogenesis in which progestins are the major proliferative stimulus. We had previously found that progestins-induced proliferation of C4HD tumors is driven by a complex bi-directional interaction among activated PR and type I and II RTKs (Balana et al., 1999 (Balana et al., , 2001 Labriola et al., 2003) . Here, we dissected a network of interactions among IGF-IR, type I RTKs and PR signaling pathways that were differentially affected by blockage of IGF-IR function Therefore, our model system has provided a unique tool to explore the molecular bases of IGF-IR contribution to breast cancer growth. A series of experimental strategies have been employed to block either IGF-IR function or expression, both in vitro and in vivo, in several tumor cell lines derived from a number of species. These included the use of neutralizing antibodies (Rohlik et al., 1987; Arteaga and Osborne, 1989) , dominant-negative receptors (Prager et al., 1994; Dunn et al., 1998; Li et al., 2000; Lee et al., 2003) , antisense and triple-helix-forming oligonucleotides (Resnicoff et al., 1994a, b) and antisense expression vectors delivered by transfection or adenovirus (Resnicoff et al., 1994a, b; Burfeind et al., 1996; Lee et al., 1996; Nakamura et al., 2000) . Startling reports from Baserga and co-workers (Resnicoff et al., 1994a, b) demonstrated that either transfection of cells with plasmids that express antisense RNA to IGF-IR or addition of ASODNs to IGF-IR mRNA were efficient at inhibiting in vitro growth of rat glioblastoma C6 cells. In addition, C6 cells stably transfected with a plasmid expressing antisense IGF-IR RNA were nontumorigenic when injected s.c. into syngeneic immunocompetent rats (Resnicoff et al., 1994a, b) . Similarly, growth of human melanoma FO-1 cells in nude mice was strongly inhibited when cells stably expressed antisense IGF-IR RNA (Resnicoff et al., 1994a) . Inhibition of tumorigenesis was also found when FO-1 cells were treated with ASODNs to IGF-IR mRNA prior to injection into nude mice (Resnicoff et al., 1994a) .
The effect of blockage of IGF-IR function by antisense techniques in breast cancer cell has been assessed in several reports. Thus, stable expression of type I IGF-IR antisense RNA by using a plasmid vector resulted in a significant decrease in IGF-I and serumstimulated growth in MCF-7 human breast cancer cells (Neuenschwander et al., 1995) . In addition, recent findings demonstrated that transfection of the highly metastatic, ER negative, MDA-MB-435s breast cancer cell line with a construct carrying antisense IGF-IR RNA resulted in a significant reduction of cell proliferation and loss of soft agar growth (Chernicky et al., 2000) . Moreover, there was suppression of tumorigenesis, reduction in the metastatic potential and prolonged survival after injection of MDA-MB-435 s cells expressing antisense IGF-IR into the mammary fat pads of immune compromised mice (Chernicky et al., 2000) . Recently, it was found that the murine mammary carcinoma cell line EMT6 transfected with an antisense IGF-IR plasmid, displayed a significant decrease in proliferation (Chernicky et al., 2002) . Tumor size decreased when cells carrying the antisense IGF-IR were injected into syngeneic mice (Chernicky et al., 2002) . It is worth pointing out that in the aforementioned studies, antisense RNA was produced intracellularly by an expression vector, in contrast to our present study in which we either injected ASODNs directly into tumors growing in mice or delivered the oligodeoxynucleotides by systemic administration through the retroorbital venous plexus. Another important difference between these studies and our present work is that most previous reports have relied on modification of cells ex vivo before inoculation to mice. Direct transmission of DNA into established tumors has proved to be feasible and safe at reducing tumor growth in experimental procedures in mice and in human clinical studies . Though to our knowledge direct injection of ASODNs to IGF-IR in mouse mammary tumors has not been previously performed, direct injection of antisense IGF-IR plasmids into established N2A tumors growing in syngeneic A/J mice resulted in marked inhibition of tumor growth (Liu et al., 1998) . As we have reported here, this effect persisted after the period of active DNA administration.
We have herein demonstrated that the antitumor effect of IGF-IR AS[S]ODNs was due to a specific antisense effect. First, inhibition of tumor growth by AS[S]ODNs was dose-dependent, and no abrogation of tumor proliferation was observed in any of the control groups. Thus, we found a significantly higher tumor growth inhibition with the high dose i.v. AS[S]ODN protocol, as compared to the low-dose treatment. Second, IGF-IR expression was inhibited in tumors from mice receiving AS [S] ODNs as compared to tumors from control groups. Our findings have provided the first evidence that two major signal transduction pathways known to be activated by IGF-IR, the PI-3K/Akt and the classical p42/p44 MAPK pathways (Scrimgeour et al., 1997 and references within, Sasaoka et al., 1994) , were abolished by in vivo treatment of mammary tumors with IGF-IR AS[S]ODNs. The PI-3K/Akt pathway originates from the interaction of IGF-IR with one of its major substrates, IRS-1 (Backer et al., 1993) , whose tyrosine phosphorylation we found significantly lower in C4HD tumors from AS[S]ODN-treated mice as compared to tumors growing in control groups. On the other hand, IGF-IR activates the MAPK/Erk signaling pathway, mainly through the Shc proteins, another IGF-IR key substrate (Sasaoka et al., 1994; Scrimgeour et al., 1997) . Our results are in accordance with recent findings (Peruzzi et al., 1999; Navarro and Baserga, 2001) showing that IGF-IR has at least three survival signals that are able to protect 32D murine hemopoietic cells from apoptosis, the PI-3K/Akt, the MAPK/Erk signaling pathways and a third one that results in the mitocondrial translocation of Raf 1, refered to as the 14.3.3 pathway. Simultaneous inactivation of two of these pathways is required to inhibit IGF-IR capacity to protect cells from apoptotic injuries. Therefore, we can hypothezise that blockage of two survival pathways achieved by in vivo administration of IGF-IR AS[-S]ODNs is directly involved in the successful inhibition of C4HD breast tumor growth. Histological evaluation of tumors from AS[S]ODN-treated mice revealed a great percentage of necrosis. We were not able to define the presence of apoptosis induced by AS[S]ODN treatment using the TdT-mediated dUTP-biotin nick end labeling (TUNEL) method (data not shown). To some extent this was an unexpected result since in many strategies involving downregulation or functional impairment of the IGF-IR, massive apoptosis of tumor cells was found (Resnicoff et al., 1995a, b) . Several explanations may be attempted. First, the rapidity of the death process makes it difficult to visualize and to quantify apoptosis. Our samples were tumors that developed in mice treated for 14 days with AS[S]ODNs. Withesell and co-workers (Liu et al., 1998) have reported results in the N2A mouse neuroblastoma cells that can provide an explanation to our findings. Transfection of N2A cells with IGF-IR antisense plasmids resulted in increase in apoptotic cells detectable at 36 h, followed by marked accumulation of necrotic cells at 48 h (Liu et al., 1998) . These results are consistent with a mechanism of cell death in which IGF-IR AS[S]ODNs induced apoptotic cell death followed by necrotic degradation of the apoptotic cells. Therefore, this latter phenomenon might apply to what we observe in our tumor samples. Nevertheless, the possibility that the prolonged and sustained abrogation of IGF-IR expression and signaling through PI-3K/Akt and p42/p44 MAPK, and the simultaneous blockage of ErbBs activation might both have led directly to cell death by necrosis.
One of the most exciting findings of our present work is that we were able to demonstrate in vivo, what we had already found in vitro: the hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 activation (Balana et al., 2001) . In fact, we extended our results to show that IGF-IR AS[S]ODN-treatment also resulted in significant decrease in the degree of ErbB-3 activation and in the amount of ErbB-2/ErbB-3 heterodimers. Our results are in line with a series of findings that have shown the involvement of IGF-IR in ErbBs signaling pathways Ram et al., 1996; Swantek and Baserga, 1999) . Our findings indicating that in vivo IGF-IR blockage in breast cancer cells results in the inactivation of ErbBs has significant therapeutical implications since it indicates that by targeting IGF-IR in breast cancer one might also achieve inhibition of ErbBs activity even in cells overexpressing ErbB-2, such as C4HD. The importance of the functional interaction between IGF-IR and ErbBs in the design of molecular strategies to block tumor growth has also been highlighted by recent findings showing that IGF-IR is able to mediate resistance to anti-EGF-R therapy in human glioblastoma cells through activation of PI-3K/Akt pathway (Chakravarti et al., 2002) .
We achieved a significant but not complete inhibition of C4HD tumor growth by IGF-IR AS[S]ODN administration, indicating that certain signaling pathways involved in C4HD cell proliferation remained unaffected by blockage of IGF-IR. Since progestins are the main proliferative stimulus in C4HD cells, the first target we explored was the PR. As measure of PR activation, we studied PR Ser294 phosphorylation state, since a series of recent findings showed that phosphorylation of PR on Ser294 directly correlated with PR transcriptional activity (Lange et al., 2000; Shen et al., 2001) . PR phosphorylation on Ser294 was detected in C4HD tumors from control groups, extending our previous in vitro findings which demonstrated that MPA was able to induce PR Ser294 phosphorylation (Labriola et al., 2003) . Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed levels of Ser294 phosphorylation comparable to those found in control groups. Several interesting conclusions on interaction between PR and IGF-IR signaling, and on the role of MAPK on PR Ser294 phosphorylation can be drawn from this result. First, in vivo abrogation of IGF-IR expression in the continuous presence of progestins has no effect on PR activity, thereby indicating that the slow proliferation of C4HD tumors after AS[S]ODN administration proceeds through a pathway driven by PR, which is IGF-IR and ErbBs-independent. Second, since abrogation of IGF-IR expression resulted in inhibition of MAPKs activity (Figure 8 ), our finding provides further support to the most recent findings by Lange and co-workers suggesting that ligand-induced PR Ser294 phosphorylation occurs via MAPK-independent pathways (Qiu et al., 2003) . In line with these observations, we have recently found that MAPK activity is not required for ligandinduced PR activity (Labriola et al., 2003) .
In summary, we have for the first time demonstrated that breast cancer growth can be inhibited by either direct intratumor injection or systemic administration of AS [S] ODNs to IGF-IR mRNA. The fact that significant though incomplete inhibition of breast tumor growth was achieved by targeting IGF-IR adds further support to increasing evidence, indicating that more than one targeted therapy is required to achieve full blockage of the multiple signaling pathways used by breast tumors to proliferate. Our finding that PR function remains unaffected by targeting IGF-IR, highlights the importance that a better understanding of the network of pathways involved in breast cancer growth will necessarily have to be developed in the design of therapeutic strategies.
Materials and methods
Animals and tumors
Experiments were carried out in virgin female Balb/c mice raised at the Institute of Biology and Experimental Medicine (IBYME) of Buenos Aires. All animal studies were conducted in accordance with the highest standards of animal care as outlined in the NIH guide for the Care and Use of Laboratory Animals and were approved by the IBYME Animal Research Committee. Hormone-dependent ductal tumor line C4HD originated in mice treated with 40 mg MPA every 3 months for 1 year, and has been maintained by serial transplantation in animals treated with 40 mg s.c. MPA depot in the opposite flank to tumor inoculum (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 . C4HD tumor line is of ductal origin and expresses PR and ER (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 ).
ODNs and [S]ODNs
Type I IGF-IR antisense oligodeoxynucleotide (5 0 TCC TCC GGA GCC AGA CTT), either phosphodiester (ASODN) or phosphorothioate (AS[S]ODN), comprises a sequence complementary to codons À29 to À24 of the signal sequence of human IGF-IR precursor (Resnicoff et al., 1994a) . Sense phosphodiester (SODN) or phosphorothioate (S[S]ODN) oligodeoxynucleotides (5 0 AAG TCT GGC TCC GGA GGA) were used as controls. ODN and [S]ODN were purchased from Biognostik (Goettingen, Germany).
Cell cultures and proliferation assays
Primary cultures of epithelial cells from C4HD tumors, growing in MPA-treated mice, were performed as previously described (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 . Epithelial cells were plated in culture flasks with DMEM/ F12 þ 5% steroid-stripped fetal calf serum (ChFCS, Gen S.A., Buenos Aires), and allowed to attach for 24-48 h. Purity of epithelial cultures was evaluated by cytokeratin staining. Cells were incubated in DMEM/F12 (without phenol red, with 100 U/ml penicillin and with 100 m/ml streptomycin), with 2.5% ChFCS in the presence of MPA 10 nM and the indicated concentrations of either phosphodiester or phosphorothioate ODNs. After a 24 h incubation, 50% of media was replaced by fresh media, and cells were incubated for another 24 h in the presence of 0.8 mCi ( 3 H)-thymidine (NEN, Dupont, Boston, MA, USA; specific activity: 70-90Ci/mmol). Cells were then trypsinized and harvested. Assays were performed in octuplicate. The differences between control and experimental groups were analysed by ANOVA followed by Tukey t-test between groups. In former experiments we had demonstrated that thymidine uptake correlates with the number of cells/well (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 ). ODN on days 8, 10, 12 and 14 and to 0.5 mg/ day/mouse of oligonucleotides on days 9, 11 and 13. In the second systemic protocol (high-dose), mice were injected with 1 mg/day/mouse AS[S]ODN, [S]ODN or 100 ml PBS from day 1 to day 14 of treatment. Tumor width and length were measured daily, in order to calculate volume. Tumor growth rates were determined as the slopes of growth curves. The percentage of tumor growth inhibition was calculated by dividing the mean tumor volume of the AS[S]ODN-treated group by the mean tumor volume of control groups, subtracting the resulting value from 1, and multiplying it by 100. Tumor growth delay was evaluated as TÀC, where T and C are the median times for treated and control tumors respectively, to reach the same volume. At day 15, half the animals from each group in all three experimental protocols were killed and tumors were removed. Tissues to be used for molecular studies were stored at À801C and tissues for histophatological analysis were fixed in 10% buffered formalin. The other half of mice in each experimental group was kept alive for one more week after the end of the treatment. Samples of liver, lung, heart and pancreas were also fixed for histological examination. Comparison of tumor volumes between the different groups during specific times was made by ANOVA followed by Tukey t-test between groups. Linear regression analysis was performed on tumor growth curves, and the slopes were compared using ANOVA followed by parallelism test to evaluate the statistical significance of the differences.
Histophatological analysis
Tumors were excised and fixed in 10% buffered formalin. Representative fragments were embedded in parafin, 5 mm sections were obtained and stained with H&E for microscopic observations.
Serum levels of glucose, creatinine, ALT and AST
The levels of glucose, creatinine, alanine aminotrasferase (ALT) and AST were measured using and Auto-Biochemical Analyzer (Autolab, Roche, Basel Switzerland) in serum samples collected at day 15 in each experimental protocol. Blood samples were taken by retroorbital bleeding.
IGF-IR, IRS-1, AKT, ErbB-2, ErbB-3, MAPK, and PR expression and activation Protein lysates from C4HD tumors growing in mice subjected to different treatments were prepared as previously described (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 ). Proteins were solubilized in sample buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol and 0.01% bromophenol blue) and subjected to SDS-PAGE. Proteins were electroblotted onto nitrocellulose. Membranes were immunoblotted with the
